Matera Maria Gabriella, Cazzola Mario
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli," Naples, Italy.
Department of Experimental Medicine, University of Rome "Tor Vergata," Rome, Italy.
Med. 2024 Jul 12;5(7):652-654. doi: 10.1016/j.medj.2024.05.011.
Chronic obstructive pulmonary disease (COPD) often involves type 1 (T1) inflammation, but 40% of patients have T2 inflammation, which worsens outcomes. Dupilumab, targeting interleukin (IL)-4 and IL-13, shows promise in phase 3 trials. The new NOTUS trial showed effectiveness in reducing exacerbations and improving lung function. However, its predominantly white population limits generalizability. Future research should include diverse populations and assess different therapies combined with dupilumab to improve outcomes.
慢性阻塞性肺疾病（COPD）常涉及1型（T1）炎症，但40%的患者存在T2炎症，这会使病情恶化。靶向白细胞介素（IL）-4和IL-13的度普利尤单抗在3期试验中显示出前景。新的NOTUS试验表明其在减少病情加重和改善肺功能方面有效。然而，其主要为白人的研究人群限制了结果的普遍性。未来的研究应纳入多样化人群，并评估与度普利尤单抗联合使用的不同疗法以改善治疗效果。
